Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
If a product is marketed through marketplaces that do not verify prescriptions, avoid it
Missing three or more doses effectively resets your body tolerance
These effects can change how other medications work too
Freezing can cause irreversible changes to the protein structure of semaglutide, rendering it ineffective or potentially unsafe
With this option, you can save up to a maximum of $563 off your 1-month supply of Zepbound with a maximum annual savings of up to $7,319 per calendar year